RT Journal Article
SR Electronic
T1 Clinical Application of Immunoreactivity of Dihydropyrimidine Dehydrogenase (DPD) in Gastric Scirrhous Carcinoma Treated with S-1, a New DPD Inhibitory Fluoropyrimidine
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2997
OP 3001
VO 25
IS 4
A1 TOSHIO SHIMIZU
A1 YASUHIDE YAMADA
A1 HISATERU YASUI
A1 KUNIAKI SHIRAO
A1 MASAHIRO FUKUOKA
YR 2005
UL http://ar.iiarjournals.org/content/25/4/2997.abstract
AB Background: A highly specific antibody against recombinant human dihydropyrimidine dehydrogenase (DPD) has been developed to immunohistochemically assess DPD expression in tumors. A new oral DPD inhibitory fluoropyrimidine (DIF), S-1, is reportedly effective against gastric scirrhous carcinoma. Patients and Methods: In this study, the relationship between immunoreactivity to DPD in biopsy specimens and the effects of chemotherapy were investigated in 61 patients treated with first-line fluoropyrimidine-based chemotherapy (S-1:DIF, 5-FU:non-DIF) for gastric scirrhous carcinoma. Results: The response rate was significantly higher in patients with DPD-positive tumors than in those with DPD-negative tumors in the S-1 group (45.5%, 10.0%: p<0.05), as compared to the 5-FU group (0%, 5.6%: p=0.398). According to the median survival time, there was no significant difference between patients with DPD-positive tumors (364 days) and those with DPD-negative tumors (406 days; p=0.626) in either the S-1 group or the 5-FU group (181 days and 256 days, respectively; p=0.543). Conclusion: This study indicates that S-1 may be effective even in gastric scirrhous carcinoma with a high level of DPD activity. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved